Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A meta-analysis of albuminuria as a surrogate endpoint for kidney failure.

Nature medicine·2025
Same author

A Case Report of Median Nerve Entrapment in a Supracondylar Humeral Fracture: Diagnosis, Treatment, and Results After 5 Years of Follow-Up.

Reports (MDPI)·2025
Same author

Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study.

Rheumatology (Oxford, England)·2025
Same author

Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Differences in association between hypoalbuminaemia and mortality among younger versus older patients on haemodialysis.

Clinical kidney journal·2025
Same journal

Proceedings of the 5th Annual UAB-UCSD O'Brien Center Symposium, March 4, San Diego, California.

Nephron. Clinical practice·2015
Same journal

Proceedings of the 19th International Conference on Continuous Renal Replacement Therapies, March 2-3, 2014, San Diego, California, USA.

Nephron. Clinical practice·2015
Same journal

Chronic kidney disease in disadvantaged populations.

Nephron. Clinical practice·2015
Same journal

Differential membrane expression of Toll-like receptors and intracellular cytokine induction in peripheral blood monocytes of patients with chronic kidney disease and diabetic nephropathy.

Nephron. Clinical practice·2015
Same journal

Correction of hyper- and hyponatraemia during continuous renal replacement therapy.

Nephron. Clinical practice·2015
Same journal

Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction.

Nephron. Clinical practice·2015
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Biosimilars and regulatory authorities.

Paola Minghetti1, Paolo Rocco, Lucia Del Vecchio

  • 1Department of Pharmaceutical Sciences P. Pratesi, Università degli Studi di Milano, Milan, Italy. paola.minghetti@unimi.it

Nephron. Clinical Practice
|August 7, 2010
PubMed
Summary
This summary is machine-generated.

Biosimilars, copies of biological medicines, face complex regulations. This review critically discusses European Medicines Agency (EMEA) guidelines, focusing on recombinant human erythropoietin (rHuEPO) biosimilars.

More Related Videos

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
07:43

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears

Published on: July 14, 2023

Related Experiment Videos

Last Updated: Jun 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
07:43

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears

Published on: July 14, 2023

Area of Science:

  • Biotechnology
  • Pharmaceutical Science
  • Regulatory Affairs

Background:

  • Patent expirations of biological medicines drive the development of biosimilars.
  • Biosimilars are similar but not identical to reference products due to manufacturing process variations.
  • Regulatory frameworks for biosimilars are complex and evolving.

Purpose of the Study:

  • To critically discuss the European Medicines Agency (EMEA) guidelines for biosimilars.
  • To focus on the specific regulatory aspects of recombinant human erythropoietin (rHuEPO) biosimilars.
  • To analyze the development and implications of updated EMEA guidelines.

Main Methods:

  • Review of existing EMEA guidelines and product-class specific guidelines.
  • Critical analysis of regulatory policies concerning biosimilars.
  • Focus on the case study of recombinant human erythropoietin (rHuEPO).

Main Results:

  • EMEA guidelines provide a framework for biosimilar approval in Europe.
  • Product-class specific guidelines, like for rHuEPO, address unique manufacturing challenges.
  • An updated draft guideline for rHuEPO reflects evolving experience and regulatory considerations.

Conclusions:

  • Navigating biosimilar regulation requires understanding complex EMEA guidelines.
  • The development of rHuEPO biosimilars highlights the need for specific regulatory approaches.
  • Continuous refinement of guidelines is essential for the safe and effective introduction of biosimilars.